Q3 2026 Financial Results Call and Webcast - STAAR SURGICAL CO

Explicit Guidance:

• FY2026 Full Year: No formal revenue or EPS guidance provided; management expects "strong full-year adjusted net income and free cash flow" driven by record nine-month performance.
• Q4 2026: Expectation of Q4 revenue to be lower sequentially compared to Q3 due to seasonality (China Q4 historically ~10% lower), though revenue is expected to grow year-over-year. No specific financial targets (revenue, margin, capex) issued for Q4 or FY2026.
• FY2027: No formal guidance issued; management will hold off on FY2027 guidance until operational milestones (specifically full capacity in Swiss facilities) are confirmed.
• Operating Expenses: On track to meet the $225 million adjusted operating expense target for the full year 2026.
• Margin Outlook: Q4 2026 gross margin expected to be above Q3 levels (implying improvement over 70.9%) due to lower tariffs and reduced inventory provisions; unit costs expected to improve in 2027 as US and Swiss facilities run at full capacity.
• Share Repurchases: Board authorized a $50 million share repurchase program; execution depends on disciplined capital allocation and market conditions.

Business-Segment Outlook:

• China: Distributor unit shipments grew 12.4% YTD; management expects shipments to distributors to reflect underlying demand more closely as supply constraints ease. Growth driven by mix shift to EvoPlus (V5) and Toric lenses (higher ASP). Mid-tier hospitals expected to continue closing the gap with top-tier centers.
• United States: Opportunity focuses on expanding total addressable market by converting patients from lasers to lenses and addressing "sideline" patients. U.S. sales to exceed $6 million per quarter for the fourth consecutive quarter.
• Emerging Markets (APAC ex-China): India and Taiwan expected to continue growth; Japan and South Korea facing headwinds (currency and market weakness).
• EMEA: 51% growth excluding the Middle East (driven by Spain, Germany, UK); Middle East growth expected to moderate as Q4 laps specific deadlines.
• Americas: 14% growth; U.S. market expected to benefit from structural shift away from declining laser procedures (down 5.8% in 2026) toward ICLs.
• Product Mix: Expect continued improvement in ASP globally as V5 and Toric ICLs capture higher market share; V5 demand outstripped supply in Q3, indicating runway for mix-driven ASP growth.

Market and Competitive Outlook:

• Structural Shift: Management expects the long-term trend of shifting from laser-based to lens-based vision correction to continue across multiple markets, citing consumer preference for "freedom from glasses/contacts" and reversibility.
• US Laser Market: Laser vision correction procedures declined 5.8% in 2026; ICL market growing double-digits, positioning STAR to capture displaced demand.
• Competitive Positioning: Evo ICL cited as the most clinically validated phakic IOL; adoption expected to deepen in mid-tier hospitals and lower diopter segments.
• Pricing: ASP durability supported by unique value proposition of Toric lenses and V5; pricing power expected to remain as mix shifts to premium products.

Macro / Industry Outlook:

• China Market: End-market demand volume expected to be stable (not "amazing"), but STAR capturing disproportionate share via mix improvement.
• South Korea: Market softness of 5–10% anticipated; management expects this to be a temporary market issue rather than a structural decline in STAR's specific positioning.
• Geopolitical/Tariffs: Transition of all China-bound ICL manufacturing to Switzerland completed in Q3; expected to reduce future tariff exposure on U.S. origin products entering China (though existing inventory remains subject to tariffs).
• FX: Currency fluctuations expected to continue impacting Japan and other Asian markets.
• Regulatory: U.S. label expansion (age 60+) adds ~8 million eligible patients; Brazil label expansion (lowered prescription) adds ~26 million eligible patients.

Strategic Initiatives:

• Manufacturing Capacity: Transition of all China-bound manufacturing to Swiss facility completed; second clean room at Nidwalden (NEDAL) secured DECRA certification to support scale.
• R&D / Innovation: First-in-human trials for two Colomer-based presbyopia products (multifocal and aspheric) expected to begin patient enrollment in "next few months" pending regulatory approval.
• Product Launch Cadence: Target to build toward a meaningful product launch in a critical market every 18 to 24 months.
• Supply Chain: Focus on increasing manufacturing yields; each 1% yield improvement estimated to generate $750k–$1M in annual incremental gross profit.
• Leadership Changes: Appointment of Ben Park (CTO) to lead R&D; David Bailey (ex-CEO) returned as CCO to drive surgeon adoption; Andrew Pilon (VP BizDev) and Pascal Ashleman (VP APAC) appointed to expand partnerships and global footprint.
• Operations: ERP system implementation completed; focus on inventory management and supply chain planning.

Risks and Headwinds to Outlook:

• Supply Constraints: Inability to fully meet demand for V5 and Toric lenses in Q3 limited revenue realization; potential for lost sales if patients do not wait for specific configurations.
• Macroeconomic & Geopolitical: Global macro and geopolitical issues could create challenges for Q4 and beyond; tariffs remain a temporary pressure on margins until Swiss transition fully takes effect.
• Market Volatility: Regional market softness in South Korea and currency headwinds in Japan could impact ex-China growth rates.
• R&D Uncertainty: Timelines for new product launches and first-in-human trials are subject to regulatory authorizations; success not guaranteed.
• Seasonality: Q4 in China historically experiences sequential volume drops compared to Q1/Q2.

Management Tone on the Future:

• Confidence: Management expresses "encouraged" and "pleased" sentiment regarding progress on revenue, profitability, and innovation, citing record nine-month results and a "debt-free" balance sheet.
• Focus: Emphasis on "discipline" and "returns-focused" capital allocation; confidence in the long-term structural shift from lasers to lenses.
• Caution: Explicitly stated they are "stopping short of predicting" specific growth rates for ex-China revenue or FY2027; cautious on Q4 due to "unknowns" and macro issues.
• Long-term View: Optimistic about becoming a "much larger company" through pipeline expansion and operational excellence, despite acknowledging the timeline required to realize these gains.

Miscellaneous:

• Regulatory Status: U.S. label eligibility now extends to age 60; Brazil prescription threshold lowered to -0.5 diopters.
• Clinical Data: Over 100,000 eyes studied and 4 million lenses distributed worldwide for Evo ICL.
• Financial Metrics: Third quarter 2026 net sales $83.4M; Adjusted EBITDA $14.4M; Free Cash Flow positive; Debt-free balance sheet with $206.4M cash.